Genetic-guided psychotropic medication choices for adults in Manitoba
Pharmacogenomics-Supported Psychotropic Prescribing Trial (PGx-SUPPORT): A Pilot Implementation Study in Manitoba
This project will test whether using a patient's genetics to guide psychotropic medication choices helps adults in Manitoba who are starting or changing psychiatric medicines.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Manitoba Academic / other |
| Locations | 2 sites (Winnipeg, Manitoba and 1 other locations) |
| Trial ID | NCT06929533 on ClinicalTrials.gov |
What this trial studies
This interventional project offers pharmacogenetic (PGx) testing using saliva samples to adults seeking mental health care in Manitoba and tracks whether test results influence prescribing. Feasibility will be measured across acceptability (patient and clinician satisfaction), practicality (turnaround time), implementation (clinicians' use of results), and demand (referrals and intent to use). Secondary outcomes include changes in global functioning and symptom severity using measures such as CGI, BPRS, PHQ-9, and GAD-7. The work is delivered through Shared Health facilities and the University of Manitoba with local clinician referrals.
Who should consider this trial
Good fit: Adults aged 18 or older in Manitoba who are starting, changing, adjusting, or augmenting psychotropic medications and who are referred by a treating clinician, can provide a saliva sample, and have a personal health identification number.
Not a fit: Patients who already have pharmacogenetic results, who are unwilling to provide a saliva sample, who lack a personal health identification number, or who have had liver or bone marrow transplants are unlikely to benefit or be eligible.
Why it matters
Potential benefit: If successful, PGx-guided prescribing could speed finding the right medication, reduce adverse reactions, and improve symptom control.
How similar studies have performed: Some prior pharmacogenetic-guided prescribing studies have shown modest improvements in medication selection and fewer adverse reactions, but results have been mixed and local feasibility in Manitoba has not been tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Aged 18 years or older * The initiation, change, dose adjustment, or augmentation of psychotropic medication(s) is indicated * The treating clinician thinks PGx testing can benefit and refers the patient to the study Exclusion Criteria: * Unwillingness to donate saliva samples for genetic analysis * History of liver or bone marrow (hematopoietic cell) transplantation * PGx testing results are already available * No personal health identification number (PHIN) is available
Where this trial is running
Winnipeg, Manitoba and 1 other locations
- Shared Health Facilities — Winnipeg, Manitoba, Canada (Not_yet_recruiting)
- University of Manitoba College of Pharmacy — Winnipeg, Manitoba, Canada (Recruiting)
Study contacts
- Principal investigator: Abdullah Al Maruf, PhD, M.Pharm., B.Pharm — University of Manitoba
- Study coordinator: Abdullah Al Maruf, BPharm, MPharm, PhD
- Email: abdullah.maruf@umanitoba.ca
- Phone: 204-318-2575
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.